Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melanie Anderson

Physician Assistant, Medical Thornton, CO Physician Assistant

NPI 1013075423 CMS profile 10768119

3655 E 104Th Ave, Thornton, CO 80233

Open in the dashboard

General payments

$13,161

780 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melanie Anderson of Thornton, CO is reported in the CMS Open Payments database as having received $13,161 across 780 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,262 115
2024 General $2,693 165
2023 General $2,921 180
2022 General $2,350 136
2021 General $2,935 184

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melanie Anderson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Melanie Anderson were reported at $2,262. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Melanie Anderson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,935 $156 $41–$563 $132
2022 $2,350 $185 $55–$649 $149
2023 $2,921 $199 $58–$717 $160
2024 $2,693 $206 $62–$740 $164
2025 $2,262 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,547 178 payments
  2. AstraZeneca Pharmaceuticals LP $1,347 66 payments
  3. Novo Nordisk Inc $1,148 64 payments
  4. Lilly USA, LLC $988 71 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $975 64 payments
  6. Amgen Inc. $492 31 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $492 24 payments
  8. Pfizer Inc. $469 33 payments
  9. Abbott Laboratories $445 30 payments
  10. Astellas Pharma US Inc $417 14 payments
  11. Other $3,840 205 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,016 777 payments
  2. Education $145 3 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,004 73 payments
  2. FARXIGA $695 29 payments
  3. RYBELSUS $642 33 payments
  4. Ozempic $623 32 payments
  5. UBRELVY $509 31 payments
  6. MOUNJARO $487 34 payments
  7. Kerendia $467 23 payments
  8. JARDIANCE Diabetes $393 27 payments
  9. BREZTRI $384 13 payments
  10. JARDIANCE Diabetes $376 27 payments
  11. Other $10,438 631 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

1,752

Median for Physician Assistant: 241

Drug cost

$146,491

Median for Physician Assistant: $4,110

Branded share of claims

22.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 18 $31,305
Jardiance Empagliflozin Brand 20 $29,946
Farxiga Dapagliflozin Propanediol Brand 17 $28,682
Ozempic Semaglutide Brand 15 $20,489
Tresiba Flextouch U-100 Insulin Degludec Brand 17 $17,796
Levothyroxine Sodium Generic 128 $1,154
Albuterol Sulfate Hfa Albuterol Sulfate Brand 26 $927
Gabapentin Generic 37 $877
Omeprazole Generic 33 $843
Atorvastatin Calcium Generic 117 $802

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$11,269

Of which drugs: $1,869

Medicare patients

66

Average age 74

Services billed

201

45 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 39%
Diabetes 32%
Ischemic heart disease 24%
Chronic kidney disease 24%
Depression 24%
COPD 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 19 19 $1,555

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$405 — —
JARDIANCE
$258 20 —
MOUNJARO
$250 — —
Veozah
$135 — —
FARXIGA
$104 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

780 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record